

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 64710

Title: Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05533129

Position: Peer Reviewer

Academic degree: MBChB, MD, MS

Professional title: Doctor, Staff Physician

Reviewer's Country/Territory: Sweden

Author's Country/Territory: Taiwan

Manuscript submission date: 2021-02-26

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-03-30 08:23

Reviewer performed review: 2021-04-05 10:39

Review time: 6 Days and 2 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Language quality	<input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection
Conclusion	<input type="radio"/> Accept (High priority) <input checked="" type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input type="radio"/> Major revision <input type="radio"/> Rejection
Re-review	<input checked="" type="radio"/> Yes <input type="radio"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous
	Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No

SPECIFIC COMMENTS TO AUTHORS

We read with interest the study by Dr. Sun HY et al. on a multicenter cohort of HIV/HCV genotype 6 patients in Taiwan. Well-written study reporting important findings on the efficacy of Sofosbuvir-based and non-Sofosbuvir based DAAs in patients living with HIV/HCV comparable to HCV mono-infected patients. Few points needed for clarification. 1. Sun HY et al reported at SVR12 93.8% and 91.2% virological response in the intention to treat analysis and 97.5%, 94.8% in the per-protocol analysis. Have you tested the predictors of non-virological response in your cohort? Was liver cirrhosis at baseline a predictor of non-virological response? 2. Please clarify in the methods section that baseline means at treatment initiation. 3. Minor comments: • Page 14: “improvement of transaminitis” consider rewording with “improvement of elevated serum transaminases” • Page 43, Table 1: Please correct “HBV RNA” to “HBV DNA” Thank you